Aventis Taxotere
Executive Summary
Supplemental indication for docetaxel for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior platinum based chemotherapy approved Dec. 23. Labeling points out that "only one of the two [clinical] trials [for the NSCLC indication] showed a clear effect on survival," but notes that one-year survival rates favored Taxotere in both trials. Labeling also warns that the 100 mg/m2 dose was unacceptably toxic in trials for the NSCLC indication. Docetaxel is already approved for second-line treatment of locally advanced or metastatic breast cancer. The new indication was recommended for approval Dec. 13 ("The Pink Sheet" Dec. 20, 1999, p. 8)
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth